Related Experiment Videos
Cardiovascular disease and dyslipidemia in women
11 Autumn St, Fifth Floor, Boston, MA 02215, USA. fwelty@caregroup.harvard.edu
Insights
Coronary heart disease (CHD) is a major killer of women, yet undertreated. Statins are recommended as the first-choice drug for women with established CHD, proving effective in reducing risk and mortality.
Area of Science:
- Cardiology
- Women's Health
- Pharmacology
Background:
- Coronary heart disease (CHD) is the leading cause of death in women, surpassing the next 16 causes combined.
- Historically, a misconception of a more benign prognosis for heart disease in women has led to less aggressive diagnosis and management.
- Understanding sex-based differences in CHD risk factors and presentation is crucial for effective treatment decisions.
Purpose of the Study:
- To review the current understanding of coronary heart disease (CHD) in women.
- To evaluate the efficacy of lipid-lowering therapies, including statins, in managing CHD in women.
- To provide evidence-based recommendations for the treatment of CHD in women.
Main Methods:
- Review of available data and randomized clinical trials on cardiovascular disease (CVD) in women.
- Analysis of studies investigating estrogen replacement therapy and lipid-lowering agents, specifically statins.
- Evaluation of treatment patterns and outcomes for women with established CHD.
Main Results:
- Estrogen replacement therapy has shown benefits for lipid levels in postmenopausal women but did not reduce CHD risk or mortality in major trials.
- Lipid-lowering therapy, including statins, effectively reduces CHD risk and mortality in women.
- Randomized trials indicate statins are as effective in women as in men for primary and secondary prevention of CHD.
- A significant proportion of women with CHD remain untreated or undertreated.
Conclusions:
- Statins should be the first-line pharmacotherapy for women with established coronary heart disease (CHD).
- For hypercholesterolemic postmenopausal women using estrogen for menopausal symptoms, adding a statin can further improve lipid profiles.
- Aggressive diagnosis and management, informed by sex-specific differences, are essential for improving outcomes in women with CHD.
Abstract:
Cardiovascular disease, primarily coronary heart disease (CHD), outnumbers the next 16 causes of death in women combined. However, the long-held belief that heart disease in women has a more benign prognosis than in men has resulted in less aggressive diagnosis and management patterns. Appreciation of the differences between men and women in CHD risk factors and presentation can assist in treatment decisions. Although estrogen replacement offers substantial beneficial effects on lipid levels in postmenopausal women, the first 2 randomized trials of estrogen alone and estrogen plus progestin, the Heart and Estrogen/Progestin Replacement Study and Estrogen Replacement and Atherosclerosis Study, observed no benefit in reducing risk of CHD death and nonfatal myocardial infarction and angiographic progression of CHD, respectively, in women with CHD. Available data show that lipid-lowering therapy reduces women's CHD risk and mortality but also indicate that a considerable proportion of women remains untreated or undertreated. Randomized trials of statins for primary and secondary prevention of coronary heart disease suggest that these agents are at least as effective for lowering coronary disease risk in women as in men. Therefore, statin drugs should be the drug of first choice for women with established CHD. Hypercholesterolemic postmenopausal women who require estrogen for menopausal symptoms may derive further reductions in low-density lipoprotein cholesterol and reductions in trigyceride levels with the addition of a statin drug.